Ameriprise
ACRS icon

Ameriprise’s Aclaris Therapeutics ACRS Stock Holding History

Ameriprise’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-318,426
Closed -$958K – 4047
2025
Q4 		$958K Sell
318,426
-959,391
-75% -$2.42M ﹤0.01% 3363
2025
Q3 		$2.43M Buy
+1,277,817
New +$2.23M ﹤0.01% 2912
2024
Q2 		– Sell
-62,974
Closed -$78.1K – 3855
2024
Q1 		$78.1K Sell
62,974
-1,786
-3% -$2.13K ﹤0.01% 3795
2023
Q4 		$68K Sell
64,760
-12,755
-16% -$38.9K ﹤0.01% 3843
2023
Q3 		$531K Buy
77,515
+1,278
+2% +$10.9K ﹤0.01% 3391
2023
Q2 		$791K Buy
76,237
+4,372
+6% +$39.6K ﹤0.01% 3272
2023
Q1 		$581K Sell
71,865
-565
-0.8% -$7.17K ﹤0.01% 3366
2022
Q4 		$1.14M Sell
72,430
-845
-1% -$13.6K ﹤0.01% 3066
2022
Q3 		$1.15M Sell
73,275
-2,047
-3% -$32.2K ﹤0.01% 3053
2022
Q2 		$1.05M Sell
75,322
-730
-1% -$10.2K ﹤0.01% 3103
2022
Q1 		$1.31M Buy
76,052
+1,794
+2% +$24.5K ﹤0.01% 3090
2021
Q4 		$1.08M Buy
+74,258
New +$1.13M ﹤0.01% 3225
2017
Q2 		– Sell
-44,887
Closed -$1.34M – 3719
2017
Q1 		$1.34M Sell
44,887
-3,259
-7% -$94K ﹤0.01% 2746
2016
Q4 		$1.31M Buy
+48,146
New +$1.23M ﹤0.01% 2839

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ameriprise's ACRS Position: Q1 2026 in Review

Ameriprise sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 318,426 shares — an estimated $958K sold.

Ameriprise first reported a position in ACRS in Q4 2016 and held it in 14 quarters. The position peaked at $2.43M in Q3 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Ameriprise reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 318,426 Aclaris Therapeutics shares in Q1 2026, an estimated $958K.
  • Ameriprise first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 14 quarters.
  • Ameriprise's Aclaris Therapeutics position peaked at $2.43M in Q3 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.